Aptinyx Inc (NASDAQ: APTX) is headed for the top in the market this morning, and for good reason. The company announced positive preclinical data, exciting investors and sending the stock on a run for the top. Today, we’ll talk about:
- The positive data;
- what we’re seeing from APTX stock as a result; and
- what we’ll be watching for ahead.
APTX Stock Heads Up On Data
As mentioned above, Aptinyx is having a great day in the market today after announcing positive preclinical data. The data came by way of press release early this morning.
In the release, the company provided data with regard to its novel NMDA receptor modulator, known as NYX-458. The company said that the data demonstrate reversal of cognitive deficits in a non-human primate model of Parkinson’s disease.
APTX also said that the data was presented last week at the 14th International Conference on Alzheimer’s & Parkinson’s Disease in Lisbon Portugal.
During the preclinical study, healthy non-human primates were trained on a batery of cognitive tests. These tests are components of the Cambridge Neuropsychological Test Automated Battery. This was done to establish a baseline of performance.
Once baseline was established, the non-human primates were treated with NYX-458. According to the company, the treatment resulted in rapid, robust, and long-lasting improvements in cognitive performance across the battery of tests.
In a statement, Norbert Riedel, Ph.D., President and CEO at APTX, had the following to offer:
With up to half of all people with Parkinson’s disease experiencing cognitive impairment and very few therapeutic options addressing these cognitive deficits, the unmet need in Parkinson’s cognitive impairment is immense.
The benefits observed in this highly translatable disease model demonstrate the potential for NYX-458 to be a much-needed improvement in treating these cognitive symptoms. It is highly encouraging that administration of NYX-458 was able to restore cognitive performance in this study – on some measures, back to healthy baseline levels – and we are eager to initiate a Phase 2 study in patients with Parkinson’s disease later this year.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Aptinyx, the news proved to be overwhelmingly positive.
After all, Alzheimer’s and Parkinson’s disease are medical conditions that lead to several challenges for the medical community. Finding solutions to these conditions could be overwhelmingly valuable.
So, it’s not surprising to see that the stock is making a run for the top in the market this morning. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:39), APTX is trading at $4.42 per share after a gain of $0.32 per share or 7.80% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on APTX. In particular, we’re interested in following the company’s work to find solutions for Alzheimer’s and Parkinson’s disease patients. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!